NCT03430284 is a Phase 4 clinical trial of Lifestyle therapy in Diabetes Mellitus, Type 2, sponsored by Shandong Provincial Hospital.

Who is sponsoring NCT03430284?

NCT03430284 is sponsored by Shandong Provincial Hospital.

What drugs are being tested in NCT03430284?

Interventions in NCT03430284: Lifestyle therapy, Pharmacotherapy, Monitoring and management, General treatment.

What condition does NCT03430284 study?

NCT03430284 studies Diabetes Mellitus, Type 2.

Is NCT03430284 still recruiting?

NCT03430284 is currently status unknown. Last updated 9 July 2021.

Last reviewed 2021-07-09 · How we verify

NCT03430284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multifactorial Intervention on Diabetes (MIDiab Study)

Status unknown Phase 4 Last updated 9 July 2021

What this trial tests

Phase 4 trial testing Lifestyle therapy in Diabetes Mellitus, Type 2 in 6,300 participants. Status unknown.

Timeline

1 April 2018

Primary endpoint
31 December 2021

31 December 2022

Quick facts

Lead sponsor	Shandong Provincial Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	6,300
Start date	1 April 2018
Primary completion	31 December 2021
Estimated completion	31 December 2022
Sites	2 locations across China

Drugs / interventions tested

Lifestyle therapy
Pharmacotherapy — full drug profile →
Monitoring and management
General treatment

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Shandong Provincial Hospital

Who can join

Adults 35 to 75, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The prevalence of diabetes mellitus has been increasing in recent decades in China, and vascular complication is the major burden in patients with type 2 diabetes. Previous studies demonstrated that only glycemic control was not effective enough to prevent or improve diabetic vascular complications, but guidelines from the Chinese Diabetes Society and other national guidelines recommend an integrated multifactorial treatment approach. In this study, we aim to evaluate the effect on diabetic vascular complications of a multifactorial intervention comprising behavior modification, polypharmacological therapy and periodical monitoring in patients with type 2 diabetes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

58<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : Stockholm, Sweden, 19 - 23 September 2022.
· 2022 · cited 6× · PMID 35920845 · DOI 10.1007/s00125-022-05755-w

Verify or expand the search:

Other trials of Lifestyle therapy

Trials testing the same drug.

NCT05416125 — Vyvanse in Children Aged 6 to 12 Years · EARLY_PHASE1 · active not recruiting
NCT04221750 — Diet and Exercise Plus Metformin to Treat Frailty in Obese Seniors · Phase 3 · completed
NCT03130426 — Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi · Phase 3 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Shandong Provincial Hospital trials

Trials by the same sponsor.

NCT07333287 — A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With A · Phase 2 · not yet recruiting
NCT07180342 — An Empirical Study on the Mechanisms of Biopsychosocial Functional Improvement in Patients With Major Depressive Disorde · NA · recruiting
NCT07284992 — SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC · Phase 2 · recruiting
NCT06908382 — Neoadjuvant QL1706 Therapy for ESCC · Phase 2 · recruiting
NCT06829797 — A Multicenter Randomized Controlled Phase II Trial of Iparomlimab and Tuvonralimab (QL1706) Combined with SOX Chemothera · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03430284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shandong Provincial Hospital
Last refreshed: 9 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03430284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing